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Abstract 
Advances in treatment have not recently been reported in rare primary vaginal 
adenocarcinomas. A 56-year-old woman with a chronic vaginal cyst and possible in utero 
diethylstilbestrol exposure presented with postmenopausal bleeding. Biopsy of the 
vagina revealed high-grade papillary serous adenocarcinoma. MRI showed a 6-cm 
vaginal tumor and 3-cm left inguinal lymph node with metastasis. The patient initially 
received concurrent cisplatin and radiation. She then received high-dose-rate 
brachytherapy for further local control. Brachytherapy following external beam radiation 
with concurrent cisplatin led to clinically undetectable cancer at 24 months with minimal 
side effects. 
 
Introduction 
Vaginal carcinomas account for 1–2% of all gynecological cancers [1]. Primary therapy 
for locally invasive disease consists of external and intracavitary or interstitial irradiation, 
except in selected early cases that may be treated surgically with local excision or with 
brachytherapy alone. Radical surgery, which may involve partial or total pelvic 
exenteration, is generally reserved for pelvic recurrence after irradiation and for patients 
with fistulas at diagnosis. We report a case of stage III primary vaginal papillary serous 
adenocarcinoma with metastasis to the left inguinal lymph nodes treated definitively with  
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external beam radiation concurrent with cisplatin followed by high-dose-rate (HDR) 
brachytherapy. 
Case Report 
A 56-year-old woman with unconfirmed in utero diethylstilbestrol exposure presented in early 2007 
with intermittent spotting of a 4-month duration. A vaginal cystic structure was present for 30 years, 
requiring intermittent aspiration. On vaginal examination, a smooth, non-tender, globular cystic 
structure was visualized on the right wall of the vagina measuring about 3 to 4 cm in diameter in the 
middle third of the vagina. A lymph node 4 cm in diameter was palpated in the left inguinal area. 
Vaginal biopsy revealed high-grade papillary serous adenocarcinoma. Metastatic workup included 
normal endocervical and endometrial biopsies, colonoscopy, mammography, and chest. 2-[
18F] fluoro-
2-deoxy-D-glucose positron emission tomography (FDG-PET) scan showed a large, slightly irregular, 
lobulated hypermetabolic mass near the midline centered slightly to the right 3 cm in the area of the 
middle third of the vagina and metastasis to the left inguinal lymph nodes. Computed tomography (CT) 
showed a 6-cm vaginal mass and 2-cm mass in the left inguinal area. MRI revealed a 6-cm tumor 
between the bladder and vagina with no invasion of the bladder mucosa and a left inguinal lymph node 
measuring 3.3 cm in largest dimension (fig. 1a). The vaginal incisional biopsy measured 0.7 × 0.3 × 0.2 
cm and was read at an academic medical center as ‘grade 2/3 clear cell and focal papillary serous 
adenocarcinoma with angiolymphatic involvement’. Immunohistochemistry staining showed positive 
CK7, progesterone receptor, and carcinoembryonic antigen with negative CK20 and estrogen receptor. 
Clinically, her tumor was stage IIIC by the AJCC staging system, T2 N1 M0 and stage II by the FIGO 
staging system. 
Discussions were held with the patient regarding all treatment options, including possible acute and 
long-term serious sequelae. Three-dimensional simulation was conducted using a computed 
tomography simulator (PET-CT Discovery –ST; GE Medical Systems, Waukesha, Wisc., USA). Target 
volumes were contoured on a Pinnacle system (Phillips Healthcare, Andover, Mass., USA). The patient 
was treated using 6-MV photons delivered with a 9-field intensity modulated radiotherapy technique to 
a total dose of 50 Gy in 25 fractions to the tumor and to 45 Gy in 25 fractions to the inguinal and pelvic 
lymph nodes (fig. 2a). She then received an electron boost using 12-MeV photons using a direct field 
technique to total dose of 30 Gy in 15 fractions to the 90% isodose line to the left inguinal lymph nodes. 
Six cycles of weekly cisplatin at 100 mg/m
2 were administered during external beam radiation. HDR 
brachytherapy delivered 45 Gy to the tumor surface using iridium-192 (fig. 2b). A multiple channel 
vaginal catheter cylinder (Intracavitary Mould Applicator; Nucletron Inc., Columbia, Md., USA) was 
inserted into the vaginal cavity. A balloon was inserted on the posterior part of the vaginal catheter. The 
balloon was inflated with 30 ml of saline with 5% contrast to position the rectum away from the high 
dose rate sources and to attenuate the radiation to further protect the posterior wall of the vagina and 
rectum. Four catheters and 80 dwelling source positions were employed to deliver 5 Gy per treatment 
session using a HDR unit. The patient experienced a limited amount of side effects during treatment 
with only grade 2 dermatitis from external beam radiation. MRI performed in between external beam 
and brachytherapy treatment (fig. 1b) showed partial response of the tumor. Complete response was 
confirmed by FDG-PET and CT scan 6 months after treatment. At 3, 6 and 18 months, the patient 
reported improving vaginal discharge at 1 pad per day. She used a dilator to prevent vaginal stenosis. 
The patient was free of recurrence 24 months after therapy. 
Discussion 
Several studies have evaluated external beam radiotherapy for vaginal 
adenocarcinoma. Two cases of adenocarcinoma were included in a series of 28 primary 
vaginal cancers treated with external beam radiotherapy and brachytherapy [2]. Frank et 
al. [3] reported 26 patients with primary vaginal adenocarcinoma treated with external 
beam radiotherapy and brachytherapy with mostly grade 1–2 toxicities. The combination 
of external beam radiotherapy and cis-platinum was described by Samant et al. [4], whose 
series included 2 cases of adenocarcinoma. In the present case, concurrent cisplatin 
appeared to sensitize the tumor to radiation since the tumor responded at a lower dose 
and at a faster rate than expected. Concurrent chemotherapy with irradiation appears to  
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significantly enhance radiation effects on cancer and cycling epithelial cells, but it does 
not appear to proportionately increase late effects in normal tissues [4]. The present case 
is unique in that we utilized both chemoradiation and brachytherapy to treat vaginal 
adenocarcinoma. 
HDR brachytherapy is an appealing treatment option for vaginal adenocarcinoma. 
HDR brachytherapy is a technique that delivers radiation to the tumor bed while 
minimizing dose inaccuracies from internal organ and patient motion [5]. Vaginal HDR 
brachytherapy has a very low incidence of side effects [6, 7] and considering the short 
treatment time, it appears cost beneficial. Side effects from vaginal brachytherapy for 
cervical cancer include acute mucositis, proctitis, and cystitis, as well as late proctitis and 
cystitis, telangiectasia, atrophy, fibrosis and stenosis [8]. In this case, MRI showed only a 
partial response after external beam treatment concurrent with cisplatin. Complete 
response was achieved after the addition of brachytherapy. The patient experienced only 
vaginal discharge during and after radiation therapy and grade 2 dermatitis during 
external-beam treatment. Despite the tumor’s proximity to the bladder, the patient did 
not develop a fistula between the bladder and vagina. In summary, chemoradiation 
followed by brachytherapy provided adequate dose to the tumor and lymph nodes for 
complete clinical response while distributing the dose to prevent severe toxicity. 
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Fig. 1. Axial T2-weighted pelvic magnetic resonance images. a Two weeks prior to treatment, the 6.0-
cm vaginal mass (arrow) and the left inguinal lymph node bed (arrowhead) are prominent. Note the 
close proximity of the primary tumor to the bladder (block arrow). b Imaging of similar section shows 
partial response to therapy after external beam radiation treatment and before brachytherapy treatment. 
The tumor appears to have central necrosis. 
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Fig. 2. Radiation treatment plans. a Intensity-modulated radiotherapy with isodose curves with 
corresponding dose. A homogeneous distribution of 45 Gy was achieved to the tumor (solid red 
shading) and inguinal lymph node beds. b HDR brachytherapy treatment plan for one fraction. Solid 
red is tumor. Circles are isodose curves in Gy: white = 25, dark blue = 12.5, light blue = 10, yellow = 
7.5, red = 5, green = 2.5. 
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